	m PTO V 5-93		attorney's docket number PU60660						
		TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	u.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) unknown 0, 585830						
		NATIONAL APPLICATION NO. US2005/001333	INTERNATIONAL FILING DATE 13 January 2005	PRIORITY DATE CLAIMED 13 January 2004					
	TITLE OF INVENTION Muscarinic Acetylcholine Receptor Antagonists								
APPLICANT(S) FOR DO/EO/US Dramane I LAINE, Michael R PALOVICH, Alexander G PRESTON, Anthony William James COOPER									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1	[x]	This is a FIRST submission	n of items concerning a filing under	35 U.S.C. 371.					
2.	[]			ncerning a filing under 35 U.S.C. 371.					
3.		X] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).							
4.	:	The US has been elected (Article 31).							
5.	[X]	 A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [] is transmitted herewith (required only if not transmitted by the International Bureau). b. [] has been transmitted by the International Bureau. c. [X] is not required, as the application was filed in the United States Receiving Office (RO/US). 							
6.	[]	A translation of the International Application into English (35 U.S.C. 371(c)(2)).							
7.	[]								
8. 9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	[]	a. [] was submitted as part of the international application under Rule 4.17(iv). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11. to 16. below concern other document(s) or information included:									
		An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.							
		A copy of the assignment document and a 1 page Statement Under 37 CRF 3.73(b).							
13.	13. [x] A FIRST preliminary amendment.								
14.	(Add claim to priority via Preliminary Amendment for US originating cases only) . [] A SECOND or SUBSEQUENT preliminary amendment.								
		A substitute specification.	sivi promining unionomem.						
	5. [X] Power of Attorney and Correspondence Address Indication Form (1 page).								
17.	7. [x] An Abstract on a separate sheet of paper (1 page).								
	8. [x] Copy of Form PCT/ISA/210.								
19.	P. [] Other items or information.								

·, -- (2) (500, 710 12 JUL 2005

us application unknown	NO. (if known see 37 CFR 1.50	D) INTERNATIONA PCT/US200	INTERNATIONAL APPLICATION NO. PCT/US2005/001333		ATTORNEYS DOCKET NO. PU60660	
20. [X] The fo	ollowing fees are submitte	ed:		CALCULATION	PTO USE ONLY	
Basic	National Fee (37 C.F.F					
■ Basic	Filing Fee	\$300.00				
	ination Fee					
	nal Preliminary Examination					
satisfy pro	visions of PCTArtlice33(1)-	\$0.00				
*All other sit	uations	4000				
Searcl	h Fee					
	(37 CFR 1.445(a)(2) has been					
			\$100.00	\$100.00		
		-	fice\$400.00	·		
*All other sit			\$500.00			
			E CALCULATIONS =	\$400.00		
	30.00 for furnishing the o			\$0.00		
	earliest claimed priority					
Claims		Jumber Extra	Rate		·-	
Total claims	12 - 20 =	0	0 x \$50.00	\$0.00		
Independent	1-3=	0	0 x \$200.00	\$0.00		
claims						
Multiple depend	ent claims (if applicable)		+ \$360.00	\$0.00		
			VE CALCULATIONS =	\$400.00		
			eets (including drawings)	\$0.00		
that exceed 100						
thereof.			SUBTOTAL =			
		\$400.00				
Processing fee of						
☐ 20 ☐ 30 moi	nths from the earliest claim					
		\$400.00	·			
				Amount to be	\$	
				refunded		
<u> </u>				charged	\$	

a.	A check in the amount of \$	to cover the above fees is enclosed
α.	L. 1 A CHECK III the amount of a	to cover the above rees is eliciosed

- b. Please charge my Deposit Account No. 19-2570 in the amount of \$400.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5019

Facsimile (610) 270-5090

SIGNATURE

Soma G. Simøn

NAME

37,444

REGISTRATION NO.

document2

3,31585830 MP6 Rec'd PCT/PTO 12 JUL 2006

PATENT ATTORNEY'S DOCKET NUMBER PU60660

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2005/001333 13 January 2005 13 January 2004

TITLE OF INVENTION

Muscarinic Acetylcholine Receptor Antagonists

APPLICANT(S) FOR DO/US

Dramane I LAINE, Michael R PALOVICH, Alexander G PRESTON, Anthony William James COOPER

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450 ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date 12 July 2006 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV757866065US addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)